American Academy of Ophthalmology
Aura has enrolled and dosed at Wills Eye Hospital the first patient in its Phase 1b clinical trial of AU-011. The company also has received FDA fast track designation for AU-011 for the treatment of primary ocular melanoma.
Aura has received IND clearance from the U.S. FDA for its lead program, light-activated AU-011 in ocular melanoma (OM). This active IND enables Aura to begin initial clinical testing of AU-011, a unique targeted therapy that could transform the primary treatment of patients with OM.
Kaliki S and Shields C L
Aura secured an additional $8 million round of funding to advance AU-011 to the clinic. The company also announced the addition of Henri Termeer, former CEO of Genzyme and major Aura investor, to its Board of Directors, and welcomed key new Clinical Advisory Board (CAB) members, all distinguished ocular oncologists.
Aura's CEO, Eli de los Pinos, will present a company overview at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2016 Annual Meeting (OIS@AAO) in Chicago on Thursday, October 13, 2016, at 11 a.m. EST.
Aura Biosciences announced today that it will participate in the Boston Miles for Melanoma 5K Run/Walk, in support of the Melanoma Research Foundation’s (MRF) research, advocacy and education efforts.
Elisabet de los Pinos, Aura's founder and CEO, will present a company overview at the 15th Annual Needham Healthcare Conference in New York, N.Y. The presentation will take place on Tuesday, April 12, 2016, at 2:40 p.m. EDT.
Laabs’ foundation and Aura Biosciences advance efforts to develop new and better therapies to treat rare cancer patients. Aura Biosciences is hoping to improve the options for future ocular melanoma patients.
Listen to this podcast to learn more about how Aura CEO Eli de los Pinos built the company from the ground up around viral-like synthetic nanoparticles that are closely related to wild type viruses in structure and behavior but lack any viral DNA.
International Journal of Cancer
Kines R, Cerio R, Roberts J, Thomson C, de los Pinos E, Lowy D, Schiller J
Click here to learn more about the newest additions to the Aura team.
Aura announced today the publication of a new paper demonstrating how its synthetic Viral-like Particles (VLP) modeled on the human papillomavirus (HPV) are able to bind uniquely to cancer cells while leaving healthy surrounding tissue unharmed.
Aura has been granted Orphan Disease Designation by the FDA for its drug AU-011 for the treatment of Uveal Melanoma.
Wall Street Journal